Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma

OBJECTIVES: Our aim was to describe our experience in using apatinib as treatment for radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC). METHODS: Forty-seven patients undergoing apatinib treatment for RAIR-DTC were prospectively enrolled in this study. The study endpoints were objec...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Wei, Shi, Xiangyu, Fang, Qigen, Zhang, Xu, Liu, Shanting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904562/
https://www.ncbi.nlm.nih.gov/pubmed/35282451
http://dx.doi.org/10.3389/fendo.2022.768028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904562/
https://www.ncbi.nlm.nih.gov/pubmed/35282451
http://dx.doi.org/10.3389/fendo.2022.768028

Ejemplares similares